According to the results of two independent data monitoring committees, the planned duration of clinical trials of the gene therapy drug Neovasculgen for the treatment of interstitial cystitis has been reduced by two years. In addition, positive preliminary data on the effectiveness of the drug allow us to hope for early registration of a new indication befo...

Artgen's RAS net profit for 9 months of 2025 amounted to 266.4 million rubles, an increase of 20.7% compared to 220.7 million rubles in the previous year. Revenue increased 2.5 times to ₽290.5 million against ₽114.9 million a year earlier.

Artgen's net profit under IFRS for 6 months of 2025 amounted to ₽132.43 million, an increase of 27.9% compared to ₽103.58 million in the previous year. Revenue increased by 12.6% to ₽838.87 million against ₽745.12 million a year earlier.

Artgen's RAS net profit for 6 months of 2025 amounted to ₽44.7 million, a 2.5-fold decrease from ₽113.2 million in the previous year. Revenue increased by 15.6% to ₽74.3 million from ₽64.3 million a year earlier.